Sponsor Dossier
Janssen-Cilag
Sponsor Dossier for Janssen-Cilag. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: CONCERTA
- Brand: DARZALEX
- Brand: DUROGESIC
- Brand: EDURANT
- Brand: EPREX
- Brand: ERLYAND
- Brand: IMBRUVICA
- Brand: INTELENCE
- Device (sponsor): Electric infusion pump administration set
- Device (sponsor): Infusion administration set, infusion pump
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
About
Janssen-Cilag is an Australian Private Company with ABN 47000129975, registered in New South Wales and currently active. The company operates under the trading names Johnson & Johnson Innovative Medicine and Johnson & Johnson Innovation.
Portfolio
Janssen-Cilag has 36 brands on the ARTG, of which 34 are indexable. The company has 33 brands with Product Information on file, 26 brands with PBAC outcome(s) on record, and 15 brands with AusPAR(s) on record. Notable brands include CONCERTA, DARZALEX, DUROGESIC, EDURANT, EPREX, ERLYAND, IMBRUVICA, INTELENCE, INVEGA, JANSSEN, JAXIMAB, and LAZCLUZE.
Therapeutic focus
The portfolio is distributed across the following therapeutic areas: — Oncology: 13 brands — Neurology: 6 brands — Infectious Disease: 5 brands — Immunology: 5 brands — Cardiology: 5 brands — Gastroenterology: 1 brand — Dermatology: 1 brand
PBS footprint
Janssen-Cilag has 21 brands with at least one PBS-listed item, with the latest PBS schedule date touched by the portfolio on 1 May 2026.
Regulatory activity
The most recent PBAC outcome for Janssen-Cilag was on 1 July 2025, with 26 brands holding PBAC outcomes on record. The most recent AusPAR was dated 9 April 2025, with 15 brands holding AusPARs on record.